Mint-Losartan: Azide Impurity
Summary
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot / Batch No. |
|---|---|---|---|---|---|
Mint |
Mint-Losartan/HCTZ 50mg/12.5mg |
DIN 02389657 |
Tablet |
Losartan 50mg Hydrochlorohiazide 12.5mg |
2005006959, 2005006960, 2005006961, 2005006962, 2005006963, 2005011154, 2005011156 |
Mint |
Mint-Losartan/HCTZ 100mg/12.5mg |
DIN 02389665 |
Tablet |
Losartan 100mg Hydrochlorohiazide 12.5mg |
2005006807, 2005006808, 2005006809, 2005006810, 2105002149 |
Mint |
Mint-Losartan/HCTZ 100mg/25mg |
DIN 02389673 |
Tablet |
Losartan 100mg Hydrochlorohiazide 25mg |
1805012687, 1805012688, 1805012689, 1805012792, 1905001010, 1905001011, 2005006947, 2005006949, 2005006950, 2005006951, 2005007297, 2005007298, 2005013776, 2105002150 |
Issue
Presence of impurity Losartan Azide ((5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole)) above the acceptable concentration limit in affected lots.
Related recalls and alerts
Additional information
Background
Depth of Recall: Retailers, Wholesalers
Details
Mint Pharmaceuticals Inc
6575 Davand Drive,
Mississauga, ON, L5T 2M3, Canada
Get notified
Receive notifications for new and updated recalls and alerts by category.